Publications
Publications Co-Authored by Lundbeck Scientists
Our commitment to science is reflected in our track record of publications. Here are the most recent publications co-authored by Lundbeck scientists.
| Article | Product | Authors | Publication links | Year | Journal |
| A large-scale genome-wide gene expression analysis in peripheral blood identifies very few differentially expressed genes related to antidepressant treatment and response in patients with Major Depression Disorder | Vortioxetine | Nøhr AK, Lindow M, Forsingdal A, Demharter S, Nielsen T, Buller R, Moltke I, Vitezic M, Albrechtsen A | Read publication | 2021 | Neuropsychopharmacology |
| A Noninterventional Cohort Study Assessing Time to All-Cause Treatment Discontinuation After Initiation of Aripiprazole Once-Monthly or Daily Oral Atypical Antipsychotic Treatment in Patients With Schizophrenia | Aripiprazole | Such P, Bøg M, Kabra M, Jørgensen KT, de Jong-Laird AC | Read publication | 2021 | The Primary Care Companion for CNS Disorders |
| Adherence and persistence among patients with major depressive disorder enrolled in the vortioxetine tAccess patient support program | Vortioxetine | Lawrence D, Manjelievskaia J, Chrones L, McCue M, Touya M | Read publication | 2021 | Current Medical Research & Opinion |
| Agitation in dementia: real-world impact and burden on patients and the healthcare system |
Brexpiprazole | Jones E, Aigbogun MS, Pike J, Berry M, Houle CR, Husbands J | Read publication | 2021 | Journal of Alzheimer's Disease |
| An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection |
Aripiprazole | Wang Y, Wang X, Harlin M, Larsen F, Panni M, Yildirim M, Madera J, Forbes A, Mustafa N, Ruiz-White I, Raoufinia A | Read publication | 2021 | Current Medical Research & Opinion |
| An integrated pharmacokinetic-pharmacodynamic-pharmacoeconomic modelling method to evaluate treatments for adults with schizophrenia | Aripiprazole | Piena M, Houwing N, Kraan C, Wang X, Waters H, Duffy R, Mallikaarjun S, Bennison C | Read publication | 2021 | PharmacoEconomics |
| An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants |
Brexpiprazole | Dean F. Wong; Suresh Malikaarjun; Arash Raoufinia; Patricia Bricmont; James R. Brašić; Robert D. McQuade; Robert A. Forbes; Tetsuro Kikuchi; Hiroto Kuwabara | Read publication | 2021 | European Journal of Clinical Pharmacology |
| Anti-Aβ antibody Aducanumab regulates the proteome of senile plaques and closely surrounding tissue in a transgenic mouse model of Alzheimer’s disease |
N/A | Bastrup J, Hansen K, Poulsen T, Kastaniegaard K, Asuni AA, Christensen S, Belling D, Stensballe A, Volbracht C | Read publication | 2021 | Journal of Alzheimer's Disease |
| Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: Associations with clinical and treatment outcomes in the AtWoRC Study |
Vortioxetine | Chokka P, Ge H, Bougie J, Ettrup A, Clerzius G | Read publication | 2021 | Therapeutic Advances in Psychopharmacology |
| Are self-reported and self-monitored adherence good proxies for reaching relevant plasma concentrations? Experiences from a study of anti-depressants in healthy volunteers | Vortioxetine | Larsen KG, Areberg J, Åström DO | Read publication | 2021 | Clinical Trials |
| Brexpiprazole blocks Posttraumatic stress disorder-like memory and promotes normal fear memory | Brexpiprazole | Ducourneau E-G, Guette C, Perrot D, Mondesir M, Mombereau C, Arnt J, Desmedt A, Piazza P-V | Read publication | 2021 | Molecular Psychiatry |
| Changes in antidepressant therapy should be considered early in patients with inadequate response to a first-line agent | Vortioxetine | Bernhard T Baune, Falkai P | Read publication | 2021 | Australian and New Zealand Journal of Psychiatry |
| Chronobiologic parameter changes in patients with major depressive disorder and sleep disturbance treated with adjunctive brexpiprazole: an open-label, flexible-dose, exploratory substudy |
Brexpiprazole | Krystal AD, Mittoux A, Lindsten A, Baker RA | Read publication | 2021 | Journal of Affective Disorders |
| Clinical immunogenicity evaluation of Eptinezumab, a therapeutic humanized monoclonal antibody for the preventive treatment of migraine | Eptinezumab | Pederson S, Biondi D, Allan B, Cady R, Schaeffler B, Baker B, Latham J | Read publication | 2021 | Frontiers in Immunology |
| Combined analysis of safety information in international joint / domestic clinical trials of vortioxetine for patients with depression | Vortioxetine | Osawa S, Nakajima A, Fujimoto S, Ogino Y, Moriguchi Y, Inoue T | Read publication | 2021 | Rinsho Yakuri (Japanese Journal of Clinical Pharmacology) |
| Design and Synthesis of Pyrrolo[2,3 d]pyrimidine-derived Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors using a Checkpoint Kinase 1 (CHK1)-derived Crystallographic Surrogate |
N/A | Williamson D, Smith G, Mikkelsen G, Jensen T, Acheson-Dossang P, Badolo L, Bedford S, Chell V, Jen Chen I, Dokurno P, Hentzer M, Newland S, Ray S, Shaw T, Surgenor A, Terry L, Wang Y, Christensen K | Read publication | 2021 | Journal of Medicinal Chemistry |
| Droxidopa persistence in neurogenic orthostatic hypotension may be affected by titration approach | Droxidopa | F Amjad, B Polenchar, A Favit | Read publication | 2021 | International Journal of General Medicine |
| Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment |
Vortioxetine | Fagiolini A, Florea I, Loft H, Christensen MC | Read publication | 2021 | Journal of Affective Disorders |
| Effects of brexpiprazole across symptom domains in patients with schizophrenia: post hoc analysis of short- and long-term studies | Brexpiprazole | Marder S, Meehan SR, Weiss C, Chen D, Hobart M, Hefting N | Read publication | 2021 | Schizophrenia Bulletin |
| Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial | Eptinezumab | Winner P, McAllister P, Chakhava G, Ailani J, Ettrup A, Josiassen MK, Lindsten A, Mehta L, Cady R | Read publication | 2021 | JAMA: Journal of the American Medical Association |
| Efficacy of vortioxetine on anhedonia: results from a pooled analysis of short-term studies in patients with major depressive disorder | Vortioxetine | McIntyre R, Loft H, Christensen MC | Read publication | 2021 | Neuropsychiatric Disease and Treatment |
| Exploring patient experiences taking adjunctive brexpiprazole for major depressive disorder: analysis of exit interviews | Brexpiprazole | Weiss C, Meehan SR, Brown TM, Gupta C, Mørup MF, Thase ME, McIntyre RS, Ismail Z | Read publication | 2021 | Journal of Patient-Reported Outcomes |
| External validation of a population pharmacokinetic model of vortioxetine using therapeutic drug monitoring data | Vortioxetine | Frederiksen T, Smith RL, Wollmann BM, Areberg J, Molden E | Read publication | 2021 | Clinical Pharmacokinetics |
| Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review | Brexpiprazole | Brockbank J, Krause T, Moss E, Milthers Pedersen A, Frank Mørup M, Ahdesmäki O, Vaughan J, Brodtkorb T-H | Read publication | 2021 | Health and Quality of Life Outcomes |
| Impact of Agitation in Long-Term Care Residents with Dementia in the United States | Brexpiprazole | Fillit H, Aigbogun MS, Gagnon-Sanschagrin P, Cloutier M, Davidson M, Serra E, Guérin A, Baker RA, Houle CR, Grossberg G | Read publication | 2021 | International Journal of Geriatric Psychiatry |
| Impact of depression onset and treatment on the trend of annual medical costs in Japan: a database study using employer based health insurance claims data | Vortioxetine | Cho Y, Mishiro I, Fujimoto S, Nakajima T | Read publication | 2021 | Advances in Therapy |
| In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole | Brexpiprazole | Sasabe H, Koga T, Furukawa M, Matsunaga M, Sasahara K, Nemoto H, Hashizume K, Ohzone Y, Amunom I, Torii M, Umehara K, Kashiyama E, Takeuchi K | Read publication | 2021 | Xenobiotica |
| In vivo and in vitro pharmacokinetic characterization of a novel serotonin-dopamine activity modulator brexpiprazole and a main metabolite in rat, monkey and human |
Brexpiprazole | Sasabe H, Koga T, Furukawa M, Matsunaga M, Kaneko Y, Koyama N, Hirao Y, Akazawa H, Kawabata M, Kashiyama E, Takeuchi K. | Read publication | 2021 | Xenobiotica |
| Incremental burden of comorbid major depressive disorder in patients with type 2 diabetes or cardiovascular disease: a retrospective claims analysis | Vortioxetine | Kangethe A, Lawrence DF, Touya M, Chrones L, Polson M, Evangelatos T | Read publication | 2021 | BMC Health Services Research |
| Long-term safety and tolerability of eptinezumab in patients with chronic migraine: A 2-year, open-label, phase 3 trial | Eptinezumab | Kudrow D, Cady R, Allan B, Pederson S, Hirman J, Mehta L., Schaeffler B. | Read publication | 2021 | BMC Neurology |
| Management of Neurogenic Orthostatic Hypotension in Neurodegenerative Disorders: A Collaboration Between Cardiology and Neurology | Droxidopa | F Amjad, S Beinart | Read publication | 2021 | Neurology and Therapy |
| Management Strategies for Comorbid Supine Hypertension in Patients With Neurogenic Orthostatic Hypotension | Droxidopa | Isaacson S, Dashtipour K, Mehdirad A, Peltier A | Read publication | 2021 | Current Neurology and Neuroscience Reports |
| New Drug and Biologics Approvals in 2019: A Systematic Analysis of Patient Experience Data in FDA Drug Approval Packages and Product Labels |
N/A | Schultz-Knudsen K, Sabaliauskaite U, Hellsten J, Blaedel Lassen A, Vinther Morant A | Read publication | 2021 | Therapeutic Innovation & Regulatory Science |
| Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate |
Aripiprazole | Such P, Olivares JM, Arias L, Berg MT, Madera J | Read publication | 2021 | Neuropsychiatric Disease and Treatment |
| Patient and physician perspectives of depressive symptoms and expectations for treatment outcome: results from a web-based survey |
Vortioxetine | Ishigooka J, Hoshino T, Imai T,Yoshida H, Ono M, Ota M, Moriguchi Y, Fujikawa K, Shintani A, Fernandez J | Read publication | 2021 | Neuropsychiatric Disease and Treatment |
| Patient expectations and experience of the early phases of antidepressant therapy for major depressive disorder: A qualitative study |
Vortioxetine | Baune BT, Florea I, Ebert B, Touya M, Ettrup A, Hadi M, Ren H | Read publication | 2021 | Neuropsychiatric Disease and Treatment |
| Patient-Identified Most Bothersome Symptom in Preventive Migraine Treatment With Eptinezumab: A Novel Patient Centered Outcome | Eptinezumab | Lipton R, Dodick D, Ailani J, McGill L, Hirman J, Cady R | Read publication | 2021 | Headache: The Journal of Head and Face Pain |
| Phosphodiesterase type 1 inhibition Alters medial prefrontal cortical activity and reward-driven behaviour and Partially reverses neurophysiological deficits in the rat phencyclidine model of schizophrenia |
N/A | Hayes J, Laursen B, Eneberg E, Kehler J, Rasmussen L, Langgard M, Bastlund J, Gerdjikov T |
Read publication | 2021 | Neuropsychopharmacology |
| Prediction of residual cognitive disturbances by early response of depressive symptoms to antidepressant treatments in patients with major depressive disorder | Vortioxetine | Sumiyoshi T, Hoshino T, Mishiro I, Hammer-Helmich L, Ge H, Moriguchi Y, Fujikawa K, Fernandez J | Read publication | 2021 | Journal of Affective Disorders Reports |
| Predictors and trajectories of treatment response to SSRIs in patients suffering from PTSD |
Brexpiprazole | Anne Krogh Nøhr, Hans Eriksson, Mary Hobart, Ida Moltke, Raimund Buller, Anders Albrechtsen, Stinus Lindgreen | Read publication | 2021 | Psychiatry Research |
| Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study |
Aripiprazole | Olivares JM, González-Pinto A, Páramo M | Read publication | 2021 | European Psychiatry |
| Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache | Eptinezumab | Marmura MJ, Diener HC, Cowan RP, Tepper SJ, Diamond ML, Starling AJ, Hirman J, Mehta L, Brevig T, Cady R | Read publication | 2021 | Headache: The Journal of Head and Face Pain |
| Quantification of in vivo metabolic activity of CYP2D6 genotypes and alleles through population pharmacokinetic analysis of vortioxetine |
Vortioxetine | Frederiksen T, Areberg J, Schmidt E, Stage TB, Brosen K | Read publication | 2021 | Clinical Pharmacology & Therapeutics |
| Redefining Expectations for Migraine Prevention | Eptinezumab | Cady R, Gottschalk C, Pavlovic J | Read publication | 2021 | US Neurology |
| Relationship of subjective cognitive impairment with psychosocial function and relapse of depressive symptoms in patients with major depressive disorder: analysis of longitudinal data from PERFORM-J |
Vortioxetine | Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Hammer-Helmich L, Fernandez J | Read publication | 2021 | Neuropsychiatric Disease and Treatment |
| Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials | Eptinezumab | Smith T, Spierings E , Cady R, Hirman J, Schaeffler B, Werther S, Shen V, Spierling B, Brevig T, Josiassen M, Brunner E, Mehta L, Honeywell L | Read publication | 2021 | The Journal of Headache and Pain |
| Safety of switching to brexpiprazole in Japanese patients with schizophrenia: a post-hoc analysis of a long-term open label study | Brexpiprazole | Ishigooka J, Inada K, Niidome K, Aoki K, Kijima Y, Iwashita S, Yamada S | Read publication | 2021 | Human Psychopharmacology: Clinical and Experimental, Psychiatry and Clinical Neurosciences |
| Schein et al. Prevalence of post-traumatic stress disorder in the United States: A systematic literature review | Brexpiprazole | Schein J, Houle C, Urganus A, Cloutier M, Patterson-Lomba O, Wang Y, King S, Levinson W, Guerin A, Lefebvre P, Davis LL | Read publication | 2021 | Current Medical Research & Opinion |
| Simultaneous Modelling of Alzheimer’s Disease Progression via Multiple Cognitive Scales | N/A | Kühnel L, Berger A-K, Markussen B, Raket L | Read publication | 2021 | Statistics in Medicine |
| Systemic administration of Ivabradine, an HCN channel inhibitor, blocks spontaneous absence seizures | N/A | Iacone Y, Morais T, David F, Delicata F, Parri R, Weisser J, Bundgaard C, Vestergaard Klewe I, Thomsen M, Crunelli V, Lőrincz M | Read publication | 2021 | Epilepsia |
| Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients | Eptinezumab | Baker B, Schaeffler B, Hirman J, Hompesch M, Peterson S, Smith J | Read publication | 2021 | Endocrinology, Diabetes & Metabolism |
| Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection | Aripiprazole | Fitzgerald HM, Shepherd J, Bailey H, Berry M, Wright J, Chen M | Read publication | 2021 | Neuropsychiatric Disease and Treatment |
| Two randomized, placebo-controlled double-blind trials and one open-label long-term trial of brexpiprazole for the acute treatment of bipolar mania | Brexpiprazole | Eduard Vieta, Gary Sachs, Denise Chang, Johan Hellsten, Claudette Brewer, Tim Peters Strickland, Nanco Hefting | Read publication | 2021 | Journal of Psychopharmacology |
| Using the goal attainment scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open label, multicenter study | Vortioxetine | McCue M, Sarkey S, Eramo A, François C, Parikh SV | Read publication | 2021 | BMC Psychiatry |
| Validation of the oxford depression questionnaire: sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting | Vortioxetine | Christensen MC, Fagiolini A, Florea I, Loft H, Cuomo A, Goodwin G | Read publication | 2021 | Journal of Affective Disorders Reports |
| Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety and optimal timing of dose adjustment | Vortioxetine | Christensen MC, McIntyre RS, Florea I, Loft H, Fagiolini A | Read publication | 2021 | CNS Spectrums |
| A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study | Vortioxetine | Jacobsen P, Zhong W, Xu R, Nomikos G | Read publication | 2020 | Journal of Affective Disorders |
| A PET Occupancy Study of Brexpiprazole at Dopamine D2 and D3 Receptors, Serotonin 5-HT1A and 5-HT2A Receptors, and Serotonin Reuptake Transporters in Subjects With Schizophrenia | Brexpiprazole | Girgis R, Abi-Dargham A, Forbes, A, Slifstein M | Read publication | 2020 | Neuropsychopharmacology |
| A Questionnaire-Based Evaluation of the Attitude of European Physicians towards the Use of Antipsychotic Long-Acting Injectables | Aripiprazole | Heres S, Patel M, Bent-Ennakhil N, Sapin C, di Nicola S | Read publication | 2020 | BMC Psychiatry,European Neuropsychopharmacology |
| A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder | Vortioxetine | Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I | Read publication | 2020 | Rinsho Yakuri (Japanese Journal of Clinical Pharmacology) |
| Cardiovascular Disorders Mediated by Autonomic Nervous System Dysfunction | Droxidopa | Mehdirad A, Khemani P | Read publication | 2020 | Cardiology in Review |
| Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram | Vortioxetine | Jacobsen PL, Zhong W, Nomikos GG, Affinito J, Cutler AJ, Clayton | Read publication | 2020 | CNS Spectrums |
| Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine | Eptinezumab | Houts, C, Wirth R, McGinley J, Cady R, Lipton R, | Read publication | 2020 | Headache: The Journal of Head and Face Pain |
| Effect of brexpiprazole on impulsivity in schizophrenia: a task-based functional magnetic resonance imaging study | Brexpiprazole | van Erp TGM, Baker RA, Cox K, Okame T, Kojima Y, Eramo A, Potkin SG | Read publication | 2020 | Psychiatry Research: Neuroimaging |
| Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma | Vortioxetine | Christensen MC, Florea I, Loft H, McIntyre RS | Read publication | 2020 | Journal of Affective Disorders |
| Efficacy, Tolerability, and Safety of Eptinezumab in Patients with a Dual Diagnosis of Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2 | Eptinezumab | Diener HC, Marmura M, Tepper S, Cowan R, Starling A, Diamond M, Hirman J, Mehta L, Brevig T, Sperling B, Cady R | Read publication | 2020 | Headache: The Journal of Head and Face Pain |
| Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing | Eptinezumab | Dodick D, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S | 2020 | ||
| Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 study | Eptinezumab | Silberstein S, Diamond M, Hindiyeh N, Biondi D, Cady R, Hirman J, Allan B, Pederson S, Schaeffler B, Smith J, | Read publication | 2020 | The Journal of Headache and Pain |
| Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study | Eptinezumab | Smith T, Janelidze M, Chakhava G, Cady R, Hirman J, Allan B, Pederson S,Smith J, Schaeffler B, | Read publication | 2020 | Clinical Therapeutics |
| Eptinezumab in episodic migraine: The randomized, double-blind, placebo-controlled PROMISE-1 study | Eptinezumab | Ashina M, Saper J, Cady R, Schaeffler B, Biondi D, Hirman J, Pederson S, Allan B, Smith J | Read publication | 2020 | Cephalalgia |
| Impact of atypical antipsychotics as adjunctive therapy on psychiatric cost and utilization in patients with major depressive disorder | Brexpiprazole | Yan T, Greene M, Chang E, Houle C, Tarbox M, Broder MS | Read publication | 2020 | ClinicoEconomics and Outcomes Research |
| Impact of cognitive symptoms on health-related quality of life and work productivity in Chinese patients with major depressive disorder: results from the PROACT study | Vortioxetine | Wang G, Tan KHX, Ren H, Hammer-Helmich L | Read publication | 2020 | Neuropsychiatric Disease and Treatment |
| Improvements in workplace productivity in working patients with major depressive disorder: results from the AtWoRC study | Vortioxetine | Chokka P, Bougie J, Tvistholm AH, Clerzius G, Ettrup A | Read publication | 2020 | Journal of Occupational and Environmental Medicine |
| Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: A 7-day randomized, double-blind, placebo-controlled exploratory study | Vortioxetine | Rancans E, Zambori J, Dalsgaard M, Baayen C, Areberg J, Ettrup A, Florea I | Read publication | 2020 | International Clinical Psychopharmacology |
| Neurobiology of TRS: Research Roadmap | Lu AF35700 | Kane J, Potkin S, Correll C, Agid O, Olfson M, Lindenmayer JP, Marder S, Howes O | Read publication | 2020 | npj Schizophrenia |
| Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls | Droxidopa | LeWitt P, Kymes S, Hauser R | Read publication | 2020 | Aging and Disease |
| Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine | Droxidopa | Mobarek S | Read publication | 2020 | |
| Pharmacologic Characterization of ALD403, a Potent Neutralizing Humanized Monoclonal Antibody Against the Calcitonin Gene-Related Peptide | Eptinezumab | Garcia-Martinez L, Raport C, Ojala E, Dutzar B, Anderson K, Stewart E, Kovacevich B, Baker B, Billgren J, Scalley-Kim M, Karasek C, Allison D, Latham J | Read publication | 2020 | Journal of Pharmacology and Experimental Therapeutics |
| Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine | Eptinezumab | Baker B, Schaeffler B, Beliveau M, Rubets I | 2020 | Pharmacology Research & Perspectives |
|
| Post hoc analysis of a randomized, placebo-controlled, active-reference 6-week study of brexpiprazole in patients with acute schizophrenia | Brexpiprazole | Marder SR, Eriksson H, Zhao Y, Hobart M | Read publication | 2020 | Acta Neuropsychiatrica |
| Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study | Brexpiprazole | Ishigooka J, Usami T, Iwashita S, Kojima Y, Matsuo S | 2020 | ||
| PROMISE–2: Efficacy and safety of eptinezumab in patients with chronic migraine | Eptinezumab | Lipton R, Goadsby P, Smith J, Schaeffler B, Biondi D, Hirman J, Pederson S, Allan B, Cady R | Read publication | 2020 | Neurology |
| Psychiatric Cost in Patients with Schizophrenia Treated with Oral Atypical Antipsychotic Therapy | Brexpiprazole |
Yan T, Greene M, Chang E, Houle C, Waters HC, Tarbox M, Broder MS | Read publication | 2020 | Clinical Therapeutics |
| Real-World Droxidopa or Midodrine Treatment Persistence in Patients With Neurogenic Orthostatic Hypotension or Orthostatic Hypotension | Droxidopa | Kymes S, Jackson K, Sullivan, C, Raj S | Read publication | 2020 | Autonomic Neuroscience: Basic & Clinical |
| Real-World Patient Experience with Sexual Dysfunction and Antidepressant use in Depressed Patients: A Cross-Sectional Survey Study | Vortioxetine | Paula L. Jacobsen, Eileen M. Thorley, Christopher Curran, Emil Chiauzzi | Read publication | 2020 | Neurology, Psychiatry and Brain Research |
| Reliability and validity of the 6‑item Headache Impact Test in chronic migraine from the PROMISE‑2 study | Eptinezumab | Houts CR, McGinley JS, C, Wirth RJ, Cady R, Lipton RB, | Read publication | 2020 | Quality of Life Research |
| Risk of major depressive disorder in Japanese cancer patients: A matched cohort study using employer-based health insurance claims data | Vortioxetine | Akechi T, Mishiro I, Fujimoto S, Murase K | Read publication | 2020 | Psycho-Oncology |
| Risk of major depressive disorder in spouses of cancer patients in Japan: a cohort study using health-insurance based claims data | Vortioxetine | Akechi T, Mishiro I, Fujimoto S, Murase K | Read publication | 2020 | Psycho-Oncology |
| Successfully treated patients with vortioxetine versus venlafaxine: A simplified cost-effectiveness analysis in Asian patients with major depressive disorder | Vortioxetine | Wang G, Zhao K, Reynaud-Mougin C, Loft H, Ren H, Eriksen H-LF, Ettrup A | Read publication | 2020 | Current Medical Research & Opinion |
| Symptoms of major depressive disorder and psychosocial functioning in the different phases of the disease: does the perspective of patients and healthcare providers differ? | Vortioxetine | Christensen MC, Wong J, Baune BT | Read publication | 2020 | Frontiers in Psychiatry |
| The Impact of the Food and Drug Administration Antipsychotic Drug Boxed Warning on Psychiatric Medication Use, Health Events, and Quality of Life in Elderly Dementia Patients | Brexpiprazole | Annalisa Rubino, Myrlene Sanon, Michael Ganz, Alex Simpson, Miram Fenton, Sumit Verma, Ann Hartry, Ross Baker, Ruth Duffy, Keva Gwin, Howard Fillit | Read publication | 2020 | JAMA Network Open |
| The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: A report on global assessment of functioning and the WHO wellbeing index | Aripiprazole | Schöttle D, Janetzky W, Luedecke D, Beck E, Correll CU, Wiedemann K |
Read publication | 2020 | BMC Psychiatry |
| Treatment of major depressive disorder in Japanese patients with cancer: a matched cohort study using employer-based health insurance claims data | Vortioxetine | Akechi T, Fujimoto S, Mishiro I, Murase K |
Read publication | 2020 | Clinical Drug Investigation |
| Using self-reported vocational functioning measures to identify working patients with impaired functional capacity in major depressive disorder | Vortioxetine | Murthy V, Xu R, Zhong W, Harvey P | Read publication | 2020 | Journal of Affective Disorders |
| 6-Month Use of Droxidopa for Neurogenic Orthostatic Hypotension |
Droxidopa | Francois C, Shibao CA, Biaggioni I, Duhig AM, McLeod K, Ogbonnaya A, Quillen A, Cannon J, Padilla C, Kymes S, Yue B | Read publication | 2019 | Movement Disorders Clinical Practice |
| A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as adjunctive therapy in adults with major depressive disorder | Brexpiprazole | Hobart M, Zhang P, Brewer C, Hefting N | Read publication | 2019 | Journal of Clinical Psychopharmacology |
| A new principal stratum estimand investigating the treatment effect in patients who would comply, if treated with a specific treatment | Brexpiprazole | Groes Larsen K, Krog Josiassen M | Read publication | 2019 | Statistics in Biopharmaceutical Research |
| A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder | Vortioxetine | Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I | Read publication | 2019 | Psychiatry and Clinical Neurosciences |
| A Systematic Literature Review Identifying Associations Between Outcomes and Quality of Life (QoL) or Health Care Resource Utilisation (HCRU) in Schizophrenia | Lu AF35700 | Germain N, Weatherall J, Kymes S, Löf E, Jakubowska A, François C | Read publication | 2019 | Journal of Medical Economics |
| Adapting the goal attainment approach for major depressive disorder | Vortioxetine | McCue M, Parikh S, Mucha L, Sarkey S, Cao C, Eramo A, Opler M, Lind B, Francois C | Read publication | 2019 | Neurology and Therapy |
| Agitation in patients with dementia: a systematic review of epidemiology and association with severity and course | Brexpiprazole | Anatchkova M, Brooks A, Swett L, Hartry A, Duffy RA, Baker RA, Hammer-Helmich L, Sanon Aigbogun M | Read publication | 2019 | International Psychogeriatrics |
| Anti-tau antibody-mediated clearance in mouse microglia cultures requires Fcγ-receptor interaction and functional lysosomes | AF87908 Tau | Andersson CR, Falsig J, Stavenhagen JB, Christensen S, Kartberg F, Rosenqvist N, Finsen B, Pedersen JT | Read publication | 2019 | Scientific Reports |
| Assessment of current clinical practices for major depression in Japan using a web-based questionnaire | Vortioxetine | Hori H, Kentaro Y | Read publication | 2019 | Neuropsychiatric Disease and Treatment |
| Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5-HT2A receptors in rats | Brexpiprazole | Amada N, Akazawa H, Ohgi Y, Maeda K, Sugino H Kurahashi N, Kikuchi T, Futamura T | Read publication | 2019 | Neuropsychopharmacology Reports |
| Burden of Care for Treatment-Resistant Schizophrenia: A Quantitative Caregiver Survey of Experiences, Attitudes and Perceptions | Lu AF35700 | Velligan D, Brain C, Bouérat Duvold L, Agid O, | Read publication | 2019 | Frontiers in Psychiatry |
| Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine | Vortioxetine | Lachaine J, Beauchemin C, Bibeau J, Patenaude J, Chokka P, Proulx J, Bougie J |
Read publication | 2019 | CNS Spectrums |
| Characteristics, Burden and Pharmacotherapy of Treatment-Resistant Schizophrenia: Results From a Survey of 204 US Psychiatrists | Lu AF35700 | Correll CU, Brevig T, Brain C | Read publication | 2019 | BMC Psychiatry |
| Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia | Lu AF35700 | Agid O, Baldwin M, Correll C, Howes O, Kane J, Lindenmayer JP, Marder S, Olfson M, Potkin S | Read publication | 2019 | Journal of Clinical Psychiatry |
| Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram | Vortioxetine | Jacobsen PL, Zhong W, Nomikos GG, Affinito J, Cutler AJ, Clayton | Read publication | 2019 | CNS Spectrums |
| Cognitive symptoms in major depressive disorder: Associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China | Vortioxetine | Wang G, Si T-M, Li L-J, Fang Y-R, Wang C-X, Wang L-N, Tan K H X, Ettrup A; Eriksen F H-L, Luo S, Ge L | Read publication | 2019 | Neuropsychiatric Disease and Treatment |
| Comparisons of Global Tests on Intersection Hypotheses and Their Application in Matched Parallel Gatekeeping Procedures | Brexpiprazole | Ouyang J, Zhang P, Carroll KJ, Lee J, Koch G | Read publication | 2019 | Journal of Biopharmaceutical Statistics |
| Creation and validation of a linear index to measure the health state of patients with depression in automated healthcare databases | Vortioxetine | Touya M, Lamy FX, Tanaescu A, Saragoussi D, Francois C, Wade A, Llorca PM, Lancon C, Falissard B | Read publication | 2019 | Journal of Market Access & Health Policy |
| Development of a Classifier to Identify Patients with Probable Lennox–Gastaut Syndrome in Health Insurance Claims Databases Via Random Forest Methodology | Clobazam | Vekeman F, Piña-Garza JE, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Duh MS, Shen V, Saurer TB, Montouris GD, Isojarvi J | Read publication | 2019 | Current Medical Research & Opinion |
| Differences in perceptions of major depressive disorder symptoms and treatment priorities between patients and health care providers across the acute, post-acute, and remission phases of depression | Vortioxetine | Baune B, Christensen MC | Read publication | 2019 | Frontiers in Psychiatry |
| Drug-Drug Interactions With Concomitant Clobazam and Cannabidiol Usage in Refractory Seizures | Clobazam | Tolbert D, Klein P, Gidal B | Read publication | 2019 | Epilepsy & Behavior |
| Early Initiation of Long-Acting Injectable Antipsychotic Treatment is Associated with Lower Hospitalization Rates and Healthcare Costs in Patients with Schizophrenia: Real-World Evidence From US Claims Data | Aripiprazole | Munday J, Broder MS, Chang E, Hartry A, Yan TJ, Greene M |
Read publication |
2019 | Current Medical Research & Opinion |
| Economic burden of relapse/recurrence in patients with major depressive disorder | Vortioxetine | Gauthier G, Mucha L, Shi S, Guerin A | Read publication | 2019 | Journal of Drug Assessment |
| Effect of brexpiprazole on agitation and hostility in patients with acute schizophrenia | Brexpiprazole | Citrome L, Ouyang J, Meehan SR, Baker RA, Weiss C | Read publication | 2019 | Journal of Clinical Psychopharmacology |
| Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain | Vortioxetine | Yang K-C, Stepanov V, Amini N, Martinsson S, Takano A, Bundgaard C, Bang-Andersen B, Sanchez C, Halldin C, Farde L, Finnema SJ | Read publication | 2019 | Neuropsychopharmacology |
| Effects of vortioxetine and escitalopram on electroencephalographic recordings – A randomized, crossover trial in healthy males | Vortioxetine | Nissen TD, Laursen B, Viardot G, l´Hostis P, Danjou P, Sluth LB, Gram M, Bastlund JF, Christensen SR, Drewes AM | Read publication | 2019 | Neuroscience |
| Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis | Vortioxetine | Jacobson W, Harvey P, Zhong W, Nomikos G, Olsen CK, Christensen M | Read publication | 2019 | Current Medical Research & Opinion |
| Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies | Brexpiprazole | Thase M, Hobart M, Zhang P, Weiss C, Meehan SR | Read publication | 2019 | Expert Opinion on Pharmacotherapy |
| Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials | Brexpiprazole | Grossberg G, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, Slomkowski M, Baker RA, McQuade R, Cummings J | Read publication | 2019 | American Journal of Geriatric Psychiatry |
| Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma | Vortioxetine | Christensen MC, Florea I, Loft H, McIntyre RS | Read publication | 2019 | Journal of Affective Disorders |
| Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial | Eptinezumab | Dodick DW, Lipton RB, Silberstein S, Goadsby P4, Biondi D, Hirman J, Cady R, Smith J | Read publication | 2019 | Cephalalgia |
| Exploration of treatment-resistant schizophrenia subtypes based on a survey of 204 US psychiatrists | Lu AF35700 | Correll CU, Brevig T, Brain C | Read publication | 2019 | Neuropsychiatric Disease and Treatment |
| Health-related quality of life outcomes, economic burden and cost associated among diagnosed and undiagnosed depression patients in Japan | Vortioxetine | Yamabe K, Liebert R, Flores N | Read publication | 2019 | ClinicoEconomics and Outcomes Research |
| Identifying and Characterizing Treatment-Resistant Schizophrenia in Observational Database Studies | Lu AF35700 | Jonsson L, Simonsen J, Brain C, Kymes S, Watson L | Read publication | 2019 | International Journal of Methods in Psychiatric Research |
| Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: A 2-week, randomized, double-blind, placebo-controlled study | Vortioxetine | Vieta E, Florea I, Schmidt S N, Areberg J, Ettrup A | Read publication | 2019 | International Clinical Psychopharmacology |
| Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder: results from the AtWoRC study | Vortioxetine | Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A | Read publication | 2019 | CNS Spectrums |
| Management of Coexistent Neurogenic Orthostatic Hypotension and Supine Hypertension | Droxidopa | Cannom D | Read publication | 2019 | Journal of Clinical Hypertension |
| Management of Depression in Adolescents in Japan | Escitalopram | Saito T, Reines E, Florea I, Dalsgaard M | Read publication | 2019 | Journal of Child and Adolescent Psychopharmacology |
| Medication adherence, health service use, and costs in patients with major depressive disorder initiating adjunctive antipsychotic treatment | Brexpiprazole | Broder MS, Greene M, Yan T, Chang E, Hartry A, Yermilov I | Read publication | 2019 | Clinical Therapeutics |
| Neurogenic Orthostatic Hypotension: A Nonmotor Symptom of Parkinson Disease | Droxidopa | Low P, Cutsforth-Gregory J | Read publication | 2019 | Neurology and Therapy |
| Open-label, Multicenter, Phase 3 Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-moderate Alzheimer’s Disease | Idalopirdine | Frölich L, Alireza A, Ballard C, Tariot P, Molinuevo JL, Boneva N, Geist M, Raket L, Cummings J | Read publication | 2019 | Journal of Alzheimer's Disease |
| Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls | Droxidopa | LeWitt P, Kymes S, Hauser R | Read publication | 2019 | Aging and Disease |
| Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial | Vortioxetine | Jacobsen P, Zhong W, Nomikos G, Clayton A | Read publication | 2019 | The Journal of Sexual Medicine |
| Patient attitudes towards and goals for MDD treatment: A survey study | Vortioxetine | McNaughton E, Granskie J, Curran C, Opler M, Sarkey S, Mucha L, Eramo A, Francois C, Webber-Lind B, McCue M | Read publication | 2019 | Patient Preference and Adherence |
| Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study | Vortioxetine | Haro JM, Hammer-Helmich L, Saragoussi D, Ettrup A, Larsen KG | Read publication | 2019 | Neuropsychiatric Disease and Treatment |
| Pharmacokinetics and safety of vortioxetine in the Chinese population | Vortioxetine | Miao J, Wang G, Hou J, Areberg J, Zhao Y, Højer AM, Ettrup A | Read publication | 2019 | Advances in Therapy |
| Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide | Eptinezumab | Moldovan Loomis C, Dutzar B, Ojala EW, Hendrix L, Karasek C, Scalley-Kim M, Mulligan J, Fan P, Billgren J, Rubin V, Boshaw H, Kwon G, Marzolf S, Stewart E, Jurchen D, Pederson SM, Perrino McCulloch L, Baker B, Cady RK, Latham JA, Allison D, Garcia-Martinez LF | Read publication | 2019 | Journal of Pharmacology and Experimental Therapeutics |
| Pharmacometrics of Clobazam in Pediatrics: Prediction of Effective Clobazam Doses for Dravet Syndrome | Clobazam | Tolbert D, Chu H-M, Ette EI | Read publication | 2019 | Epilepsy Research |
| Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis | Vortioxetine | Liguori C, Ferini-Strambi L, Izzi F, Mari L, Manfredi N, D'Elia A, Mercuri NB, Placidi F | Read publication | 2019 | British Journal of Clinical Pharmacology |
| Psychometric validation of Japanese version of Alcohol Quality of Life Scale (AQoLS) in the treatment of patients with alcohol use disorder – a non-interventional, prospective, longitudinal, multi-site cohort study | Nalmefene | Higuchi S, Moriguchi Y, Tan KHX | Read publication | 2019 | Quality of Life Research |
| Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study | Aripiprazole | Mustafa S, Bougie J, Miguelez M, Clerzius G, Rampakakis E, Proulx J, Malla A | Read publication | 2019 | BMC Psychiatry |
| Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: cross sectional analysis of baseline data from PERFORM-J | Vortioxetine | Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Tan K, Hammer-Helmich L, Fernandez J | Read publication | 2019 | Journal of Affective Disorders |
| Results and validation of an index to measure health state of patients with depression in automated healthcare databases | Vortioxetine | Lamy FX, Falissard B, Francois C, Lancon C, Llorca PM, Tanaescu A, Touya M, Verpillat P, Wade A, Saragoussi D | Read publication | 2019 | Journal of Market Access & Health Policy |
| Results of a Real-World Study of Vortioxetine in Patients with Major Depressive Disorder in South East Asia (REVIDA): Subgroup Analysis of Malaysian Patients | Vortioxetine | Chin CN, Azhar, Au YKC, Chong MSwee Woon, Yen TH, Yeoh BBD, Yap CH, Ku RKA, Keira JH | Read publication | 2019 | Malaysian Journal of Psychiatry |
| Role of Nurses and Nurse Practitioners in the Recognition, Diagnosis, and Management of Neurogenic Orthostatic Hypotension | Droxidopa | Biswas D, Karabin B, Turner D | Read publication | 2019 | International Journal of General Medicine |
| Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials. | Vortioxetine | Mahableshwarkar A, Jacobsen P, Affinito J, Reines E, Xu J, Nomikos G | Read publication | 2019 | CNS Spectrums |
| Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies | Aripiprazole | Madera JJ, Such P, Zhao C, Baker RA | Read publication | 2019 | Neuropsychiatric Disease and Treatment |
| The effect of aripiprazole once monthly on personal and social functioning: Post hoc analyses of acute and long-term studies | Aripiprazole | Peters-Strickland T, Baker RA, Such P, Zhang P, Madera JJ | Read publication | 2019 | Neuropsychiatric Disease and Treatment |
| The patient perspective on cognitive symptoms in major depressive disorder: a retrospective database and prospective survey analysis | Vortioxetine | Chiauzzi E, Drahos J, Sarkey S, Curran C, Wang V, Tomori D | Read publication | 2019 | Journal of Participatory Medicine |
| Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine | Vortioxetine | Nierenberg AA, Loft H, Olsen CK | Read publication | 2019 | Journal of Affective Disorders |
| Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient With Cardiovascular Disease and Parkinson Disease: A Case Report | Droxidopa | McCullough P | Read publication | 2019 | Cardiology and Therapy |
| Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis | Brexpiprazole | Sanon Aigbogun M, Stellhorn R, Hartry A, Baker RA, Fillit H | Read publication | 2019 | BMC Neurology |
| Use of Droxidopa for the Long-Term Treatment of Neurogenic Orthostatic Hypotension | Droxidopa | Hewitt LA, Raj S | Read publication | 2019 | European Heart Journal |
| Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment | Aripiprazole | Madera JJ, Such P, Zhang P, Baker RA, Grande I | Read publication | 2019 | Neuropsychiatric Disease and Treatment |
| Using self-reported vocational functioning measures to identify working patients with impaired functional capacity in major depressive disorder | Vortioxetine | Murthy V, Xu R, Zhong W, Harvey P | Read publication | 2019 | Journal of Affective Disorders |
| Utility of Autonomic Testing for the Efficient Diagnosis and Effective Pharmacologic Management of Neurogenic Orthostatic Hypotension | Droxidopa | Suleman, A; Bin Alam, S; Almardini W | Read publication | 2019 | BMJ Case Reports |
| Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized double-blind, placebo-controlled proof-of-concept study | Vortioxetine | Biederman J, Lindsten A, Sluth L B, Petersen M L, Ettrup A, Eriksen H-L F, Fava M | Read publication | 2019 | Journal of Psychopharmacology |
| Wearable Technology for High-Frequency Cognitive and Mood Assessment in Major Depressive Disorder: Longitudinal Observational Study. | Vortioxetine | Cormack F, McCue M, Taptiklis N, Skirrow C, Glazer E, Panagopoulos E, van Schaik TA, Fehnert B, King J, Barnett JH | Read publication | 2019 | JMIR Mental Health |